id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id FDA-2009-D-0539-0002,FDA,FDA-2009-D-0539,Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins; Guidance,Other,Guidance,2009-12-04T05:00:00Z,2009,12,2009-12-04T05:00:00Z,2010-02-03T04:59:59Z,2016-04-11T14:26:47Z,,0,0,0900006480a6350f FDA-2009-D-0539-0001,FDA,FDA-2009-D-0539,Draft Guidance for Industry on Assay Development for Immunogenicity Testing of Therapeutic Proteins; Availability,Notice,Notice of Availability,2009-12-04T05:00:00Z,2009,12,2009-12-04T05:00:00Z,2010-02-03T04:59:59Z,2016-04-11T14:24:08Z,E9-28960,0,0,0900006480a62b67